MET vs MS

For growth investors, Morgan Stanley (MS) is the stronger pick with 16.

8% revenue growth year-over-year, versus 10. 2% for MetLife, Inc. (MET). MetLife, Inc. (MET) offers the better valuation at 16. 7x trailing P/E (8. 2x forward), making it the more compelling value choice. Analysts rate MetLife, Inc. (MET) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, MetLife, Inc.

(MET) is the cheapest at 16. 7x versus Morgan Stanley at 24. 3x. On forward P/E, MetLife, Inc. is actually cheaper at 8. 2x.

Over the past 5 years, Morgan Stanley (MS) delivered a total return of +142.

2%, compared to +35. 3% for MetLife, Inc. (MET). Over 10 years, the gap is even starker: MS returned +739. 4% versus MET's +156. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MetLife, Inc.

(MET) is the lower-risk stock at 1. 09β versus Morgan Stanley's 1. 37β — meaning MS is approximately 26% more volatile than MET relative to the S&P 500. On balance sheet safety, MetLife, Inc. (MET) carries a lower debt/equity ratio of 70% versus 3% for Morgan Stanley — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Morgan Stanley (MS) is pulling ahead at 16.

8% versus 10. 2% for MetLife, Inc. (MET). On earnings-per-share growth, the picture is similar: Morgan Stanley grew EPS 53. 5% year-over-year, compared to -19. 2% for MetLife, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Morgan Stanley (MS) is the more profitable company, earning 13.

0% net margin versus 4. 4% for MetLife, Inc. — meaning it keeps 13. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MS leads at 17. 1% versus 6. 0% for MET. At the gross margin level — before operating expenses — MS leads at 55. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MetLife, Inc.

(MET) trades at 8. 2x forward P/E versus 16. 3x for Morgan Stanley — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MET: 20. 4% to $96. 50.

All stocks in this comparison pay dividends.

MetLife, Inc. (MET) offers the highest yield at 2. 8%, versus 2. 0% for Morgan Stanley (MS).

For long-horizon retirement investors, Morgan Stanley (MS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2.

0% yield, +739. 4% 10Y return). Both have compounded well over 10 years (MS: +739. 4%, MET: +156. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MET is a mid-cap deep-value stock; MS is a large-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.